WO1998031355A3 - Composition pharmaceutique - Google Patents

Composition pharmaceutique Download PDF

Info

Publication number
WO1998031355A3
WO1998031355A3 PCT/GB1998/000105 GB9800105W WO9831355A3 WO 1998031355 A3 WO1998031355 A3 WO 1998031355A3 GB 9800105 W GB9800105 W GB 9800105W WO 9831355 A3 WO9831355 A3 WO 9831355A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease
methyl
propylnorapomorphine
cathecol
pharmaceutical composition
Prior art date
Application number
PCT/GB1998/000105
Other languages
English (en)
Other versions
WO1998031355A2 (fr
Inventor
Dereck Alan Woodcock
Original Assignee
Britannia Pharmaceuticals Ltd
Dereck Alan Woodcock
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Britannia Pharmaceuticals Ltd, Dereck Alan Woodcock filed Critical Britannia Pharmaceuticals Ltd
Publication of WO1998031355A2 publication Critical patent/WO1998031355A2/fr
Publication of WO1998031355A3 publication Critical patent/WO1998031355A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne un médicament destiné au traitement de la maladie de Parkinson, lequel se présente sous la forme d'un emballage contenant une dose de sels physiologiquement acceptables de N-propyl norapomorphine (NPA) ou de promédicaments de ceux-ci et une dose d'un inhibiteur de catéchol-O-méthyl-transférase (COMT).
PCT/GB1998/000105 1997-01-16 1998-01-14 Composition pharmaceutique WO1998031355A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9700855.1 1997-01-16
GB9700855A GB2321190B (en) 1997-01-16 1997-01-16 Pharmaceutical composition

Publications (2)

Publication Number Publication Date
WO1998031355A2 WO1998031355A2 (fr) 1998-07-23
WO1998031355A3 true WO1998031355A3 (fr) 1998-09-11

Family

ID=10806094

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1998/000105 WO1998031355A2 (fr) 1997-01-16 1998-01-14 Composition pharmaceutique

Country Status (2)

Country Link
GB (1) GB2321190B (fr)
WO (1) WO1998031355A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI109453B (fi) * 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US20040076968A1 (en) * 2000-07-14 2004-04-22 Gonzalo Acuna Method for detecting pre-disposition to hepatotoxicity
FI20012242A0 (fi) * 2001-11-19 2001-11-19 Orion Corp Uudet farmaseuttiset yhdisteet

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2373530A1 (fr) * 1976-12-13 1978-07-07 Sterling Drug Inc Diesters de n-propylnorapomorphine, et leur utilisation comme medicaments
US4469695A (en) * 1980-02-25 1984-09-04 Ayerst, Mckenna & Harrison, Inc. 2-(4-Hydroxyalkyl-1-piperazinyl)-2,4,6-cycloheptatrien-1-one derivatives
US5496836A (en) * 1994-05-05 1996-03-05 Mount Sinai School Of Medicine Of The City University Of New York Use of famotidine and related compounds in the treatment of movement disorders
WO1996037226A2 (fr) * 1995-05-26 1996-11-28 Pfizer Inc. Combinaisons pour le traitement de la maladie de parkinson contenant des antagonistes de nmda

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3717643A (en) * 1967-05-04 1973-02-20 Sterling Drug Inc N-substituted-norapomorphines

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2373530A1 (fr) * 1976-12-13 1978-07-07 Sterling Drug Inc Diesters de n-propylnorapomorphine, et leur utilisation comme medicaments
US4469695A (en) * 1980-02-25 1984-09-04 Ayerst, Mckenna & Harrison, Inc. 2-(4-Hydroxyalkyl-1-piperazinyl)-2,4,6-cycloheptatrien-1-one derivatives
US5496836A (en) * 1994-05-05 1996-03-05 Mount Sinai School Of Medicine Of The City University Of New York Use of famotidine and related compounds in the treatment of movement disorders
WO1996037226A2 (fr) * 1995-05-26 1996-11-28 Pfizer Inc. Combinaisons pour le traitement de la maladie de parkinson contenant des antagonistes de nmda

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
COUDORE ET AL: "Effect of Tolcapone on Plasma and Striatal Apomorphine Disposition in Rats", NEUROREPORT, vol. 8, no. 4, 3 March 1997 (1997-03-03), pages 877 - 880, XP002065840 *
KOPIN: "The Pharmacology of Parkinson's Disease Therapy: An Update", ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, vol. 33, 1993, pages 467 - 495, XP002065844 *
KUNTZER ET AL: "Treatment of Parkinson's Disease", EUROPEAN EUROLOGY, vol. 36, no. 6, November 1996 (1996-11-01), pages 396 - 408, XP002065845 *
LIMOUSIN ET AL: "Acute Administration of Levodopa-Benserazide and Tolcapone, a COMT Inhibitor, in Parkinson's Disease", CLINICAL NEUROPHARMACOLOGY, vol. 18, no. 3, 1995, pages 258 - 265, XP002065842 *
MCKENZIE AND WHITE: "Evidence for the Methyation of Apomorphine by Catechol-O-Methyl-Transferase in vivo and in vitro", BIOCHEMICAL PHARMACOLOGY, vol. 22, 1973, pages 2329 - 2336, XP002065841 *
TÖRNWALL AND MANNISTO: "Effects of Three Types of Catechol O-Methylation Inhibitors on L-3,4-Dihydroxyphenylalanine-Induced Circling Behavior in Rats", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 250, no. 1, 1993, pages 77 - 84, XP002065843 *

Also Published As

Publication number Publication date
GB2321190B (en) 2000-09-20
GB2321190A (en) 1998-07-22
WO1998031355A2 (fr) 1998-07-23
GB9700855D0 (en) 1997-03-05

Similar Documents

Publication Publication Date Title
BG106251A (en) Levodopa (carbidopa) entacapone pharmaceutical preparation
NL301005I1 (fr)
NZ504618A (en) Controlled release therapeutic formulation for administering tolterodine maintaining a constant serum level
EP1029540A3 (fr) Utilisation de la droloxifène pour le traitement de maladies cardiovasculaires
MXPA03003895A (es) Formulaciones de hidrocodona de liberacion controlada.
WO2002042462A3 (fr) Agents therapeutiques et methodes d'utilisation de ces agents therapeutiques pour traiter une maladie amyloidogenique
HUP9903906A3 (en) Use of chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
HK1092380A1 (en) Use of plant extract in the manufacture of a medicament for treating diseases of increase bone resorption and composition thereof
EP1258245A3 (fr) Composition à libération accélérée contenant de la bromocriptine
WO2002000209A3 (fr) Analogues de gabapentine pour traiter les troubles du sommeil
CA2377174A1 (fr) Formes galeniques orales servant a administrer une combinaison fixe de tramadol et de diclofenac
IL119417A (en) Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease
IL125913A0 (en) Pharmaceutical combination preparation of an inhibitor of the sodium/hydrogen exchanger and medicament for the treatment of cardio-vascular diseases
WO1999033450A3 (fr) Agents therapeutiques
EP2138175A3 (fr) Formulations comprenant du valsartan pour traiter le diabète ou la microalbuminurie
WO1999061010A3 (fr) TRAITEMENT DE L'INFERTILITE PAR DES COMPOSES STIMULANT LA PRODUCTION D'AMPc, SEULS OU ASSOCIES A AU MOINS UN COMPOSE STIMULANT LA MEIOSE
EP0744176A3 (fr) Médicaments pour inhiber les pertes osseuses
WO1998031355A3 (fr) Composition pharmaceutique
WO2001068076A3 (fr) Enantiomere en d de la dfmo et ses procedes d'utilisation
EP0743068A3 (fr) Composition pour inhiber la perte osseuse contentant du sulfate de vanadium
IL125660A0 (en) Pharmaceutical composition comprising 2-(3,4-dimethoxycinnamoyl)-aminobenzoic acid for the aminobenzoic acid for the treatment or prevention of restenosis and its manufacture
FI953725A (fi) Ornitiiniaminotransferaasi-inhibiittorien käyttö lääkeaineen valmistamiseksi Alzheimerin taudin hoitamiseksi
HUP9802896A3 (en) Optically active piperidinoalkyl-4h-1,2,4-oxadiazine derivative, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
EP0987022A4 (fr) Medicaments de prevention ou de traitement de la recto-colite hemorragique et/ou de la maladie de crohn
HUP9900354A3 (en) Use of condensed 2,3-benzodiazepine derivatives for the preparation of pharmaceutical compositions treating and preventing diseases related with the inhibition of lipide peroxidation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA GB JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): CA GB JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998533930

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09582650

Country of ref document: US

122 Ep: pct application non-entry in european phase